Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp cut its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 31.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,943 shares of the company’s stock after selling 1,813 shares during the quarter. Mackenzie Financial Corp’s holdings in Vaxcyte were worth $248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in shares of Vaxcyte by 1,005.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,603 shares of the company’s stock worth $1,419,000 after buying an additional 20,558 shares in the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of Vaxcyte during the fourth quarter worth about $3,035,000. Wellington Management Group LLP grew its position in shares of Vaxcyte by 3.8% during the third quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock worth $234,442,000 after buying an additional 167,501 shares in the last quarter. Jennison Associates LLC grew its position in shares of Vaxcyte by 20.6% during the third quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after buying an additional 300,189 shares in the last quarter. Finally, UBS Group AG grew its position in shares of Vaxcyte by 62.2% during the third quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after buying an additional 28,483 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, SVP Mikhail Eydelman sold 1,667 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total value of $123,141.29. Following the completion of the sale, the senior vice president now owns 20,710 shares in the company, valued at $1,529,847.70. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP Elvia Cowan sold 11,678 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $74.08, for a total transaction of $865,106.24. Following the completion of the sale, the senior vice president now owns 12,480 shares in the company, valued at $924,518.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.87, for a total value of $123,141.29. Following the sale, the senior vice president now owns 20,710 shares of the company’s stock, valued at approximately $1,529,847.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,577 shares of company stock worth $5,149,735. 3.60% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on PCVX. Bank of America boosted their target price on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Friday, January 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research note on Wednesday, April 10th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $78.50.

Vaxcyte Stock Up 1.1 %

PCVX stock opened at $60.72 on Monday. Vaxcyte, Inc. has a fifty-two week low of $41.57 and a fifty-two week high of $82.04. The business has a 50 day moving average price of $67.96 and a 200 day moving average price of $61.53. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of -14.70 and a beta of 0.89.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter in the prior year, the firm posted ($0.73) earnings per share. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.